ID   NEMO_MOUSE              Reviewed;         412 AA.
AC   O88522; Q924H4;
DT   15-JUL-1999, integrated into UniProtKB/Swiss-Prot.
DT   27-JUL-2011, sequence version 2.
DT   07-APR-2021, entry version 180.
DE   RecName: Full=NF-kappa-B essential modulator;
DE            Short=NEMO;
DE   AltName: Full=IkB kinase-associated protein 1;
DE            Short=IKKAP1;
DE            Short=mFIP-3;
DE   AltName: Full=Inhibitor of nuclear factor kappa-B kinase subunit gamma;
DE            Short=I-kappa-B kinase subunit gamma;
DE            Short=IKK-gamma;
DE            Short=IKKG;
DE            Short=IkB kinase subunit gamma;
DE   AltName: Full=NF-kappa-B essential modifier;
GN   Name=Ikbkg; Synonyms=Nemo;
OS   Mus musculus (Mouse).
OC   Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi; Mammalia;
OC   Eutheria; Euarchontoglires; Glires; Rodentia; Myomorpha; Muroidea; Muridae;
OC   Murinae; Mus; Mus.
OX   NCBI_TaxID=10090;
RN   [1]
RP   NUCLEOTIDE SEQUENCE [MRNA].
RC   TISSUE=T-cell;
RX   PubMed=9657155; DOI=10.1016/s0092-8674(00)81466-x;
RA   Yamaoka S., Courtois G., Bessia C., Whiteside S.T., Weil R., Agou F.,
RA   Kirk H.E., Kay R.J., Israel A.;
RT   "Complementation cloning of NEMO, a component of the I-kappaB kinase
RT   complex essential for NF-kappaB activation.";
RL   Cell 93:1231-1240(1998).
RN   [2]
RP   NUCLEOTIDE SEQUENCE [GENOMIC DNA].
RX   PubMed=11410370; DOI=10.1016/s0378-1119(01)00492-9;
RA   Galgoczy P., Rosenthal A., Platzer M.;
RT   "Human-mouse comparative sequence analysis of the NEMO gene reveals an
RT   alternative promoter within the neighboring G6PD gene.";
RL   Gene 271:93-98(2001).
RN   [3]
RP   NUCLEOTIDE SEQUENCE [MRNA].
RC   STRAIN=BALB/cJ; TISSUE=Liver;
RA   Perelygin A.A., Perelygina L.M.;
RT   "Ikbkg gene modulates the herpes virus susceptibility in mice.";
RL   Submitted (MAY-2002) to the EMBL/GenBank/DDBJ databases.
RN   [4]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA].
RC   STRAIN=NOD;
RX   PubMed=16141072; DOI=10.1126/science.1112014;
RA   Carninci P., Kasukawa T., Katayama S., Gough J., Frith M.C., Maeda N.,
RA   Oyama R., Ravasi T., Lenhard B., Wells C., Kodzius R., Shimokawa K.,
RA   Bajic V.B., Brenner S.E., Batalov S., Forrest A.R., Zavolan M., Davis M.J.,
RA   Wilming L.G., Aidinis V., Allen J.E., Ambesi-Impiombato A., Apweiler R.,
RA   Aturaliya R.N., Bailey T.L., Bansal M., Baxter L., Beisel K.W., Bersano T.,
RA   Bono H., Chalk A.M., Chiu K.P., Choudhary V., Christoffels A.,
RA   Clutterbuck D.R., Crowe M.L., Dalla E., Dalrymple B.P., de Bono B.,
RA   Della Gatta G., di Bernardo D., Down T., Engstrom P., Fagiolini M.,
RA   Faulkner G., Fletcher C.F., Fukushima T., Furuno M., Futaki S.,
RA   Gariboldi M., Georgii-Hemming P., Gingeras T.R., Gojobori T., Green R.E.,
RA   Gustincich S., Harbers M., Hayashi Y., Hensch T.K., Hirokawa N., Hill D.,
RA   Huminiecki L., Iacono M., Ikeo K., Iwama A., Ishikawa T., Jakt M.,
RA   Kanapin A., Katoh M., Kawasawa Y., Kelso J., Kitamura H., Kitano H.,
RA   Kollias G., Krishnan S.P., Kruger A., Kummerfeld S.K., Kurochkin I.V.,
RA   Lareau L.F., Lazarevic D., Lipovich L., Liu J., Liuni S., McWilliam S.,
RA   Madan Babu M., Madera M., Marchionni L., Matsuda H., Matsuzawa S., Miki H.,
RA   Mignone F., Miyake S., Morris K., Mottagui-Tabar S., Mulder N., Nakano N.,
RA   Nakauchi H., Ng P., Nilsson R., Nishiguchi S., Nishikawa S., Nori F.,
RA   Ohara O., Okazaki Y., Orlando V., Pang K.C., Pavan W.J., Pavesi G.,
RA   Pesole G., Petrovsky N., Piazza S., Reed J., Reid J.F., Ring B.Z.,
RA   Ringwald M., Rost B., Ruan Y., Salzberg S.L., Sandelin A., Schneider C.,
RA   Schoenbach C., Sekiguchi K., Semple C.A., Seno S., Sessa L., Sheng Y.,
RA   Shibata Y., Shimada H., Shimada K., Silva D., Sinclair B., Sperling S.,
RA   Stupka E., Sugiura K., Sultana R., Takenaka Y., Taki K., Tammoja K.,
RA   Tan S.L., Tang S., Taylor M.S., Tegner J., Teichmann S.A., Ueda H.R.,
RA   van Nimwegen E., Verardo R., Wei C.L., Yagi K., Yamanishi H.,
RA   Zabarovsky E., Zhu S., Zimmer A., Hide W., Bult C., Grimmond S.M.,
RA   Teasdale R.D., Liu E.T., Brusic V., Quackenbush J., Wahlestedt C.,
RA   Mattick J.S., Hume D.A., Kai C., Sasaki D., Tomaru Y., Fukuda S.,
RA   Kanamori-Katayama M., Suzuki M., Aoki J., Arakawa T., Iida J., Imamura K.,
RA   Itoh M., Kato T., Kawaji H., Kawagashira N., Kawashima T., Kojima M.,
RA   Kondo S., Konno H., Nakano K., Ninomiya N., Nishio T., Okada M., Plessy C.,
RA   Shibata K., Shiraki T., Suzuki S., Tagami M., Waki K., Watahiki A.,
RA   Okamura-Oho Y., Suzuki H., Kawai J., Hayashizaki Y.;
RT   "The transcriptional landscape of the mammalian genome.";
RL   Science 309:1559-1563(2005).
RN   [5]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE GENOMIC DNA].
RC   STRAIN=C57BL/6J;
RX   PubMed=19468303; DOI=10.1371/journal.pbio.1000112;
RA   Church D.M., Goodstadt L., Hillier L.W., Zody M.C., Goldstein S., She X.,
RA   Bult C.J., Agarwala R., Cherry J.L., DiCuccio M., Hlavina W., Kapustin Y.,
RA   Meric P., Maglott D., Birtle Z., Marques A.C., Graves T., Zhou S.,
RA   Teague B., Potamousis K., Churas C., Place M., Herschleb J., Runnheim R.,
RA   Forrest D., Amos-Landgraf J., Schwartz D.C., Cheng Z., Lindblad-Toh K.,
RA   Eichler E.E., Ponting C.P.;
RT   "Lineage-specific biology revealed by a finished genome assembly of the
RT   mouse.";
RL   PLoS Biol. 7:E1000112-E1000112(2009).
RN   [6]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE GENOMIC DNA].
RA   Mural R.J., Adams M.D., Myers E.W., Smith H.O., Venter J.C.;
RL   Submitted (JUL-2005) to the EMBL/GenBank/DDBJ databases.
RN   [7]
RP   NUCLEOTIDE SEQUENCE [MRNA] OF 85-412, AND PROTEIN SEQUENCE OF 144-159.
RC   TISSUE=Cervix carcinoma;
RX   PubMed=9891086; DOI=10.1128/mcb.19.2.1526;
RA   Mercurio F., Murray B.W., Shevchenko A., Bennett B.L., Young D.B., Li J.W.,
RA   Pascual G., Motiwala A., Zhu H., Mann M., Manning A.M.;
RT   "IkappaB kinase (IKK)-associated protein 1, a common component of the
RT   heterogeneous IKK complex.";
RL   Mol. Cell. Biol. 19:1526-1538(1999).
RN   [8]
RP   FUNCTION.
RX   PubMed=9927690; DOI=10.1073/pnas.96.3.1042;
RA   Li Y., Kang J., Friedman J., Tarassishin L., Ye J., Kovalenko A.,
RA   Wallach D., Horwitz M.S.;
RT   "Identification of a cell protein (FIP-3) as a modulator of NF-kappaB
RT   activity and as a target of an adenovirus inhibitor of tumor necrosis
RT   factor alpha-induced apoptosis.";
RL   Proc. Natl. Acad. Sci. U.S.A. 96:1042-1047(1999).
RN   [9]
RP   IKK COMPLEX.
RX   PubMed=11080499; DOI=10.1074/jbc.m008353200;
RA   Li X.-H., Fang X., Gaynor R.B.;
RT   "Role of ikkgamma/nemo in assembly of the IkappaB kinase complex.";
RL   J. Biol. Chem. 276:4494-4500(2001).
RN   [10]
RP   PHOSPHORYLATION AT SER-369, AND MUTAGENESIS OF SER-369 AND SER-375.
RX   PubMed=11971901; DOI=10.1074/jbc.m201393200;
RA   Prajapati S., Gaynor R.B.;
RT   "Regulation of Ikappa B kinase (IKK)gamma /NEMO function by IKKbeta
RT   -mediated phosphorylation.";
RL   J. Biol. Chem. 277:24331-24339(2002).
RN   [11]
RP   INTERACTION WITH TANK AND IKBKB.
RX   PubMed=12133833; DOI=10.1074/jbc.m205069200;
RA   Chariot A., Leonardi A., Muller J., Bonif M., Brown K., Siebenlist U.;
RT   "Association of the adaptor TANK with the I kappa B kinase (IKK) regulator
RT   NEMO connects IKK complexes with IKK epsilon and TBK1 kinases.";
RL   J. Biol. Chem. 277:37029-37036(2002).
RN   [12]
RP   INTERACTION WITH TNIP1 AND TNFAIP3.
RX   PubMed=16684768; DOI=10.1074/jbc.m601502200;
RA   Mauro C., Pacifico F., Lavorgna A., Mellone S., Iannetti A., Acquaviva R.,
RA   Formisano S., Vito P., Leonardi A.;
RT   "ABIN-1 binds to NEMO/IKKgamma and co-operates with A20 in inhibiting NF-
RT   kappaB.";
RL   J. Biol. Chem. 281:18482-18488(2006).
RN   [13]
RP   UBIQUITINATION AT LYS-278; LYS-314; LYS-318; LYS-319 AND LYS-392, AND
RP   MUTAGENESIS OF LYS-278; LYS-314; VAL-316; LYS-318; LYS-319 AND LYS-392.
RX   PubMed=17728323; DOI=10.1093/hmg/ddm237;
RA   Sebban-Benin H., Pescatore A., Fusco F., Pascuale V., Gautheron J.,
RA   Yamaoka S., Moncla A., Ursini M.V., Courtois G.;
RT   "Identification of TRAF6-dependent NEMO polyubiquitination sites through
RT   analysis of a new NEMO mutation causing incontinentia pigmenti.";
RL   Hum. Mol. Genet. 16:2805-2815(2007).
RN   [14]
RP   PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT SER-380, AND IDENTIFICATION BY
RP   MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RC   TISSUE=Kidney, Lung, and Spleen;
RX   PubMed=21183079; DOI=10.1016/j.cell.2010.12.001;
RA   Huttlin E.L., Jedrychowski M.P., Elias J.E., Goswami T., Rad R.,
RA   Beausoleil S.A., Villen J., Haas W., Sowa M.E., Gygi S.P.;
RT   "A tissue-specific atlas of mouse protein phosphorylation and expression.";
RL   Cell 143:1174-1189(2010).
RN   [15]
RP   INTERACTION WITH TERF2IP.
RX   PubMed=20622870; DOI=10.1038/ncb2080;
RA   Teo H., Ghosh S., Luesch H., Ghosh A., Wong E.T., Malik N., Orth A.,
RA   de Jesus P., Perry A.S., Oliver J.D., Tran N.L., Speiser L.J., Wong M.,
RA   Saez E., Schultz P., Chanda S.K., Verma I.M., Tergaonkar V.;
RT   "Telomere-independent Rap1 is an IKK adaptor and regulates NF-kappaB-
RT   dependent gene expression.";
RL   Nat. Cell Biol. 12:758-767(2010).
RN   [16]
RP   INTERACTION WITH RIPK1.
RX   PubMed=31519886; DOI=10.1038/s41467-019-11839-w;
RA   Zhang X., Zhang H., Xu C., Li X., Li M., Wu X., Pu W., Zhou B., Wang H.,
RA   Li D., Ding Q., Ying H., Wang H., Zhang H.;
RT   "Ubiquitination of RIPK1 suppresses programmed cell death by regulating
RT   RIPK1 kinase activation during embryogenesis.";
RL   Nat. Commun. 10:4158-4158(2019).
RN   [17]
RP   X-RAY CRYSTALLOGRAPHY (2.7 ANGSTROMS) OF 250-343 IN COMPLEX WITH UBIQUITIN,
RP   UBIQUITIN-BINDING, AND MUTAGENESIS OF VAL-293; TYR-301; LYS-302; PHE-305;
RP   ARG-309; ARG-312; GLU-313; GLU-313; GLU-317 AND GLU-320.
RX   PubMed=19303852; DOI=10.1016/j.cell.2009.03.007;
RA   Rahighi S., Ikeda F., Kawasaki M., Akutsu M., Suzuki N., Kato R.,
RA   Kensche T., Uejima T., Bloor S., Komander D., Randow F., Wakatsuki S.,
RA   Dikic I.;
RT   "Specific recognition of linear ubiquitin chains by NEMO is important for
RT   NF-kappaB activation.";
RL   Cell 136:1098-1109(2009).
RN   [18]
RP   X-RAY CRYSTALLOGRAPHY (2.9 ANGSTROMS) OF 251-337, UBIQUITIN-BINDING, AND
RP   OLIGOMETRIZATION.
RX   PubMed=19854204; DOI=10.1016/j.jmb.2009.10.018;
RA   Grubisha O., Kaminska M., Duquerroy S., Fontan E., Cordier F., Haouz A.,
RA   Raynal B., Chiaravalli J., Delepierre M., Israel A., Veron M., Agou F.;
RT   "DARPin-assisted crystallography of the CC2-LZ domain of NEMO reveals a
RT   coupling between dimerization and ubiquitin binding.";
RL   J. Mol. Biol. 395:89-104(2010).
CC   -!- FUNCTION: Regulatory subunit of the IKK core complex which
CC       phosphorylates inhibitors of NF-kappa-B thus leading to the
CC       dissociation of the inhibitor/NF-kappa-B complex and ultimately the
CC       degradation of the inhibitor. Its binding to scaffolding polyubiquitin
CC       seems to play a role in IKK activation by multiple signaling receptor
CC       pathways. Also considered to be a mediator for TAX activation of NF-
CC       kappa-B. Could be implicated in NF-kappa-B-mediated protection from
CC       cytokine toxicity. Involved in TLR3- and IFIH1-mediated antiviral
CC       innate response; this function requires 'Lys-27'-linked
CC       polyubiquitination. {ECO:0000269|PubMed:9927690}.
CC   -!- SUBUNIT: Homodimer; disulfide-linked. Component of the I-kappa-B-kinase
CC       (IKK) core complex consisting of CHUK, IKBKB and IKBKG; probably four
CC       alpha/CHUK-beta/IKBKB dimers are associated with four gamma/IKBKG
CC       subunits. The IKK core complex seems to associate with regulatory or
CC       adapter proteins to form a IKK-signalosome holo-complex. The IKK
CC       complex associates with TERF2IP/RAP1, leading to promote IKK-mediated
CC       phosphorylation of RELA/p65. Part of a complex composed of NCOA2,
CC       NCOA3, CHUK/IKKA, IKBKB, IKBKG and CREBBP. Interacts with COPS3, CYLD,
CC       NALP2, TRPC4AP and PIDD1. Interacts with ATM; the complex is exported
CC       from the nucleus. Interacts with TRAF6. Interacts with IKBKE. Interacts
CC       with TANK; the interaction is enhanced by TBK1 and IKBKE. Part of a
CC       ternary complex consisting of TANK, IKBKB and IKBKG. Interacts with
CC       ZFAND5. Interacts with RIPK2. Interacts with TNIP1 and TNFAIP3; TNIP1
CC       facilitates the TNFAIP3-mediated de-ubiquitination of IKBKG. Interacts
CC       with TNFAIP3; the interaction is induced by TNF stimulation and by
CC       polyubiquitin. Interacts with NLRP10. Interacts with TANK; this
CC       interaction increases in response to DNA damage (By similarity).
CC       Interacts with USP10; this interaction increases in response to DNA
CC       damage (By similarity). Interacts with ZC3H12A; this interaction
CC       increases in response to DNA damage (By similarity). Interacts with
CC       TRIM29; this interaction induces IKBKG/NEMO ubiquitination and
CC       proteolytic degradation (By similarity). Interacts with TRIM13; this
CC       interaction leads to IKBKG/NEMO ubiquitination (By similarity).
CC       Interacts with ARFIP2 (By similarity). Interacts with RIPK1
CC       (PubMed:31519886). {ECO:0000250|UniProtKB:Q9Y6K9,
CC       ECO:0000269|PubMed:12133833, ECO:0000269|PubMed:16684768,
CC       ECO:0000269|PubMed:19303852, ECO:0000269|PubMed:20622870,
CC       ECO:0000269|PubMed:31519886}.
CC   -!- INTERACTION:
CC       O88522; Q60680: Chuk; NbExp=6; IntAct=EBI-998011, EBI-646245;
CC       O88522; O88351: Ikbkb; NbExp=7; IntAct=EBI-998011, EBI-447960;
CC       O88522; Q924T7: Rnf31; NbExp=7; IntAct=EBI-998011, EBI-647680;
CC       O88522; P62991: Ubc; NbExp=3; IntAct=EBI-998011, EBI-413074;
CC       O88522; P0CG48: UBC; Xeno; NbExp=3; IntAct=EBI-998011, EBI-3390054;
CC       O88522; P24772: VACWR196; Xeno; NbExp=2; IntAct=EBI-998011, EBI-4291651;
CC   -!- SUBCELLULAR LOCATION: Cytoplasm {ECO:0000250}. Nucleus {ECO:0000250}.
CC   -!- DOMAIN: The leucine-zipper domain and the CCHC NOA-type zinc-finger are
CC       essential for polyubiquitin binding and for the activation of IRF3.
CC       {ECO:0000250}.
CC   -!- PTM: Phosphorylation at Ser-68 attenuates aminoterminal
CC       homodimerization. {ECO:0000250}.
CC   -!- PTM: Polyubiquitinated on Lys-278 through 'Lys-63'; the ubiquitination
CC       is mediated by NOD2 and RIPK2 and probably plays a role in signaling by
CC       facilitating interactions with ubiquitin domain-containing proteins and
CC       activates the NF-kappa-B pathway. Polyubiquitinated on Lys-392 through
CC       'Lys-63'; the ubiquitination is mediated by BCL10, MALT1 and TRAF6 and
CC       probably plays a role in signaling by facilitating interactions with
CC       ubiquitin domain-containing proteins and activates the NF-kappa-B
CC       pathway. Monoubiquitinated on Lys-270 and Lys-302; promotes nuclear
CC       export. Polyubiquitinated through 'Lys-27' by TRIM23; involved in
CC       antiviral innate and inflammatory responses. Linear polyubiquitinated
CC       on Lys-111, Lys-143, Lys-226, Lys-246, Lys-270, Lys-278, Lys-285, Lys-
CC       295, Lys-302 and Lys-319; the head-to-tail polyubiquitination is
CC       mediated by the LUBAC complex and plays a key role in NF-kappa-B
CC       activation. Deubiquitinated by USP10 in a TANK-dependent and
CC       -independent manner, leading to the negative regulation of NF-kappa-B
CC       signaling upon DNA damage (By similarity). {ECO:0000250,
CC       ECO:0000250|UniProtKB:Q9Y6K9}.
CC   -!- PTM: Sumoylated on Lys-270 and Lys-302 with SUMO1; the modification
CC       results in phosphorylation of Ser-85 by ATM leading to a replacement of
CC       the sumoylation by mono-ubiquitination on these residues.
CC       {ECO:0000250}.
CC   -!- PTM: Neddylated by TRIM40, resulting in stabilization of NFKBIA and
CC       down-regulation of NF-kappa-B activity. {ECO:0000250}.
CC   ---------------------------------------------------------------------------
CC   Copyrighted by the UniProt Consortium, see https://www.uniprot.org/terms
CC   Distributed under the Creative Commons Attribution (CC BY 4.0) License
CC   ---------------------------------------------------------------------------
DR   EMBL; AF069542; AAC40153.1; -; mRNA.
DR   EMBL; AF326207; AAK69186.1; -; Genomic_DNA.
DR   EMBL; AF513109; AAP47160.1; -; mRNA.
DR   EMBL; AK154095; BAE32372.1; -; mRNA.
DR   EMBL; AL669976; -; NOT_ANNOTATED_CDS; Genomic_DNA.
DR   EMBL; CH466650; EDL29810.1; -; Genomic_DNA.
DR   CCDS; CCDS41023.1; -.
DR   RefSeq; NP_001154895.1; NM_001161423.1.
DR   RefSeq; NP_034677.2; NM_010547.2.
DR   RefSeq; XP_006527913.1; XM_006527850.2.
DR   RefSeq; XP_006527914.1; XM_006527851.2.
DR   RefSeq; XP_006527915.1; XM_006527852.2.
DR   RefSeq; XP_011245829.1; XM_011247527.2.
DR   PDB; 2V4H; X-ray; 2.90 A; A/B=251-337.
DR   PDB; 2ZVN; X-ray; 3.00 A; B/D/F/H=253-337.
DR   PDB; 2ZVO; X-ray; 2.90 A; B/D=250-339.
DR   PDB; 3F89; X-ray; 2.80 A; A/B=250-339.
DR   PDB; 3JSV; X-ray; 2.70 A; C/D=250-343.
DR   PDB; 4OWF; X-ray; 2.00 A; A/B=250-339.
DR   PDBsum; 2V4H; -.
DR   PDBsum; 2ZVN; -.
DR   PDBsum; 2ZVO; -.
DR   PDBsum; 3F89; -.
DR   PDBsum; 3JSV; -.
DR   PDBsum; 4OWF; -.
DR   BMRB; O88522; -.
DR   SMR; O88522; -.
DR   BioGRID; 200602; 50.
DR   ComplexPortal; CPX-3270; IkappaB kinase complex.
DR   CORUM; O88522; -.
DR   DIP; DIP-29811N; -.
DR   IntAct; O88522; 20.
DR   MINT; O88522; -.
DR   STRING; 10090.ENSMUSP00000109762; -.
DR   iPTMnet; O88522; -.
DR   PhosphoSitePlus; O88522; -.
DR   EPD; O88522; -.
DR   jPOST; O88522; -.
DR   MaxQB; O88522; -.
DR   PaxDb; O88522; -.
DR   PRIDE; O88522; -.
DR   ProteomicsDB; 252822; -.
DR   Antibodypedia; 73338; 1240 antibodies.
DR   Ensembl; ENSMUST00000114127; ENSMUSP00000109762; ENSMUSG00000004221.
DR   Ensembl; ENSMUST00000114128; ENSMUSP00000109763; ENSMUSG00000004221.
DR   Ensembl; ENSMUST00000114133; ENSMUSP00000109768; ENSMUSG00000004221.
DR   Ensembl; ENSMUST00000164101; ENSMUSP00000126770; ENSMUSG00000004221.
DR   GeneID; 16151; -.
DR   KEGG; mmu:16151; -.
DR   UCSC; uc009toz.2; mouse.
DR   CTD; 8517; -.
DR   MGI; MGI:1338074; Ikbkg.
DR   eggNOG; ENOG502R4ZD; Eukaryota.
DR   GeneTree; ENSGT00530000063808; -.
DR   HOGENOM; CLU_034097_0_0_1; -.
DR   InParanoid; O88522; -.
DR   TreeFam; TF326608; -.
DR   Reactome; R-MMU-1169091; Activation of NF-kappaB in B cells.
DR   Reactome; R-MMU-168638; NOD1/2 Signaling Pathway.
DR   Reactome; R-MMU-1810476; RIP-mediated NFkB activation via ZBP1.
DR   Reactome; R-MMU-202424; Downstream TCR signaling.
DR   Reactome; R-MMU-2871837; FCERI mediated NF-kB activation.
DR   Reactome; R-MMU-445989; TAK1 activates NFkB by phosphorylation and activation of IKKs complex.
DR   Reactome; R-MMU-450302; activated TAK1 mediates p38 MAPK activation.
DR   Reactome; R-MMU-450321; JNK (c-Jun kinases) phosphorylation and activation mediated by activated human TAK1.
DR   Reactome; R-MMU-4755510; SUMOylation of immune response proteins.
DR   Reactome; R-MMU-5357905; Regulation of TNFR1 signaling.
DR   Reactome; R-MMU-5357956; TNFR1-induced NFkappaB signaling pathway.
DR   Reactome; R-MMU-5607764; CLEC7A (Dectin-1) signaling.
DR   Reactome; R-MMU-5684264; MAP3K8 (TPL2)-dependent MAPK1/3 activation.
DR   Reactome; R-MMU-5689880; Ub-specific processing proteases.
DR   Reactome; R-MMU-5689896; Ovarian tumor domain proteases.
DR   Reactome; R-MMU-9020702; Interleukin-1 signaling.
DR   Reactome; R-MMU-933542; TRAF6 mediated NF-kB activation.
DR   Reactome; R-MMU-937039; IRAK1 recruits IKK complex.
DR   Reactome; R-MMU-937041; IKK complex recruitment mediated by RIP1.
DR   Reactome; R-MMU-975144; IRAK1 recruits IKK complex upon TLR7/8 or 9 stimulation.
DR   BioGRID-ORCS; 16151; 24 hits in 57 CRISPR screens.
DR   ChiTaRS; Ikbkg; mouse.
DR   EvolutionaryTrace; O88522; -.
DR   PRO; PR:O88522; -.
DR   Proteomes; UP000000589; Chromosome X.
DR   RNAct; O88522; protein.
DR   Bgee; ENSMUSG00000004221; Expressed in blood and 312 other tissues.
DR   ExpressionAtlas; O88522; baseline and differential.
DR   Genevisible; O88522; MM.
DR   GO; GO:0005737; C:cytoplasm; IDA:MGI.
DR   GO; GO:0005829; C:cytosol; ISO:MGI.
DR   GO; GO:0008385; C:IkappaB kinase complex; ISO:MGI.
DR   GO; GO:0072686; C:mitotic spindle; ISO:MGI.
DR   GO; GO:0005634; C:nucleus; ISO:MGI.
DR   GO; GO:0032991; C:protein-containing complex; ISO:MGI.
DR   GO; GO:0000922; C:spindle pole; ISO:MGI.
DR   GO; GO:0000151; C:ubiquitin ligase complex; ISO:MGI.
DR   GO; GO:0042802; F:identical protein binding; ISO:MGI.
DR   GO; GO:0070530; F:K63-linked polyubiquitin modification-dependent protein binding; IDA:MGI.
DR   GO; GO:1990450; F:linear polyubiquitin binding; ISO:MGI.
DR   GO; GO:0046872; F:metal ion binding; IEA:UniProtKB-KW.
DR   GO; GO:0042975; F:peroxisome proliferator activated receptor binding; ISO:MGI.
DR   GO; GO:0019904; F:protein domain specific binding; ISO:MGI.
DR   GO; GO:0046982; F:protein heterodimerization activity; ISS:UniProtKB.
DR   GO; GO:0042803; F:protein homodimerization activity; ISS:UniProtKB.
DR   GO; GO:0044877; F:protein-containing complex binding; ISO:MGI.
DR   GO; GO:1990459; F:transferrin receptor binding; ISO:MGI.
DR   GO; GO:0031625; F:ubiquitin protein ligase binding; ISO:MGI.
DR   GO; GO:0007250; P:activation of NF-kappaB-inducing kinase activity; IDA:MGI.
DR   GO; GO:0043276; P:anoikis; IMP:ParkinsonsUK-UCL.
DR   GO; GO:0001782; P:B cell homeostasis; IMP:MGI.
DR   GO; GO:0006974; P:cellular response to DNA damage stimulus; ISS:UniProtKB.
DR   GO; GO:0051650; P:establishment of vesicle localization; ISO:MGI.
DR   GO; GO:1902236; P:negative regulation of endoplasmic reticulum stress-induced intrinsic apoptotic signaling pathway; IMP:ParkinsonsUK-UCL.
DR   GO; GO:0010628; P:positive regulation of gene expression; IGI:ParkinsonsUK-UCL.
DR   GO; GO:0043123; P:positive regulation of I-kappaB kinase/NF-kappaB signaling; ISO:MGI.
DR   GO; GO:0016239; P:positive regulation of macroautophagy; IMP:ParkinsonsUK-UCL.
DR   GO; GO:0051092; P:positive regulation of NF-kappaB transcription factor activity; ISO:MGI.
DR   GO; GO:0045944; P:positive regulation of transcription by RNA polymerase II; ISS:UniProtKB.
DR   GO; GO:0065003; P:protein-containing complex assembly; ISO:MGI.
DR   GO; GO:0043122; P:regulation of I-kappaB kinase/NF-kappaB signaling; IBA:GO_Central.
DR   InterPro; IPR032419; CC2-LZ_dom.
DR   InterPro; IPR021063; NEMO_N.
DR   InterPro; IPR034735; NEMO_ZF.
DR   Pfam; PF16516; CC2-LZ; 1.
DR   Pfam; PF11577; NEMO; 1.
DR   PROSITE; PS51801; ZF_CCHC_NOA; 1.
PE   1: Evidence at protein level;
KW   3D-structure; Coiled coil; Cytoplasm; Direct protein sequencing;
KW   Disulfide bond; DNA damage; Isopeptide bond; Metal-binding; Nucleus;
KW   Phosphoprotein; Reference proteome; Transcription;
KW   Transcription regulation; Ubl conjugation; Zinc; Zinc-finger.
FT   CHAIN           1..412
FT                   /note="NF-kappa-B essential modulator"
FT                   /id="PRO_0000096783"
FT   ZN_FING         382..412
FT                   /note="CCHC NOA-type"
FT                   /evidence="ECO:0000255|PROSITE-ProRule:PRU01142"
FT   REGION          44..111
FT                   /note="Interaction with CHUK/IKBKB"
FT                   /evidence="ECO:0000250"
FT   REGION          150..250
FT                   /note="Interaction with TANK"
FT                   /evidence="ECO:0000269|PubMed:12133833"
FT   REGION          242..343
FT                   /note="Ubiquitin-binding (UBD)"
FT   REGION          246..358
FT                   /note="Self-association"
FT                   /evidence="ECO:0000250"
FT   REGION          249..412
FT                   /note="Required for interaction with TNFAIP3"
FT                   /evidence="ECO:0000250"
FT   REGION          250..339
FT                   /note="Linear polyubiquitin-binding, does not bind to 'Lys-
FT                   63'-linked polyubiquitin"
FT   REGION          315..336
FT                   /note="Leucine-zipper"
FT                   /evidence="ECO:0000255"
FT   REGION          375..412
FT                   /note="Interaction with CYLD"
FT                   /evidence="ECO:0000250"
FT   COILED          49..345
FT                   /evidence="ECO:0000255"
FT   MOD_RES         31
FT                   /note="Phosphoserine; by IKKB"
FT                   /evidence="ECO:0000250|UniProtKB:Q9Y6K9"
FT   MOD_RES         43
FT                   /note="Phosphoserine; by IKKB"
FT                   /evidence="ECO:0000250|UniProtKB:Q9Y6K9"
FT   MOD_RES         68
FT                   /note="Phosphoserine"
FT                   /evidence="ECO:0000250|UniProtKB:Q9Y6K9"
FT   MOD_RES         85
FT                   /note="Phosphoserine; by ATM"
FT                   /evidence="ECO:0000250|UniProtKB:Q9Y6K9"
FT   MOD_RES         369
FT                   /note="Phosphoserine; by IKKB"
FT                   /evidence="ECO:0000269|PubMed:11971901"
FT   MOD_RES         380
FT                   /note="Phosphoserine"
FT                   /evidence="ECO:0007744|PubMed:21183079"
FT   DISULFID        54
FT                   /note="Interchain"
FT                   /evidence="ECO:0000250"
FT   DISULFID        340
FT                   /note="Interchain"
FT                   /evidence="ECO:0000250"
FT   CROSSLNK        111
FT                   /note="Glycyl lysine isopeptide (Lys-Gly) (interchain with
FT                   G-Cter in ubiquitin)"
FT                   /evidence="ECO:0000250|UniProtKB:Q9Y6K9"
FT   CROSSLNK        139
FT                   /note="Glycyl lysine isopeptide (Lys-Gly) (interchain with
FT                   G-Cter in ubiquitin)"
FT                   /evidence="ECO:0000250|UniProtKB:Q9Y6K9"
FT   CROSSLNK        143
FT                   /note="Glycyl lysine isopeptide (Lys-Gly) (interchain with
FT                   G-Cter in ubiquitin)"
FT                   /evidence="ECO:0000250|UniProtKB:Q9Y6K9"
FT   CROSSLNK        226
FT                   /note="Glycyl lysine isopeptide (Lys-Gly) (interchain with
FT                   G-Cter in ubiquitin)"
FT                   /evidence="ECO:0000250|UniProtKB:Q9Y6K9"
FT   CROSSLNK        246
FT                   /note="Glycyl lysine isopeptide (Lys-Gly) (interchain with
FT                   G-Cter in ubiquitin)"
FT                   /evidence="ECO:0000250|UniProtKB:Q9Y6K9"
FT   CROSSLNK        270
FT                   /note="Glycyl lysine isopeptide (Lys-Gly) (interchain with
FT                   G-Cter in SUMO); alternate"
FT                   /evidence="ECO:0000250"
FT   CROSSLNK        270
FT                   /note="Glycyl lysine isopeptide (Lys-Gly) (interchain with
FT                   G-Cter in ubiquitin); alternate"
FT                   /evidence="ECO:0000250|UniProtKB:Q9Y6K9"
FT   CROSSLNK        276
FT                   /note="Glycyl lysine isopeptide (Lys-Gly) (interchain with
FT                   G-Cter in ubiquitin)"
FT                   /evidence="ECO:0000250|UniProtKB:Q9Y6K9"
FT   CROSSLNK        278
FT                   /note="Glycyl lysine isopeptide (Lys-Gly) (interchain with
FT                   G-Cter in ubiquitin)"
FT                   /evidence="ECO:0000269|PubMed:17728323"
FT   CROSSLNK        285
FT                   /note="Glycyl lysine isopeptide (Lys-Gly) (interchain with
FT                   G-Cter in ubiquitin)"
FT                   /evidence="ECO:0000250|UniProtKB:Q9Y6K9"
FT   CROSSLNK        295
FT                   /note="Glycyl lysine isopeptide (Lys-Gly) (interchain with
FT                   G-Cter in ubiquitin)"
FT                   /evidence="ECO:0000250|UniProtKB:Q9Y6K9"
FT   CROSSLNK        302
FT                   /note="Glycyl lysine isopeptide (Lys-Gly) (interchain with
FT                   G-Cter in SUMO); alternate"
FT                   /evidence="ECO:0000250"
FT   CROSSLNK        302
FT                   /note="Glycyl lysine isopeptide (Lys-Gly) (interchain with
FT                   G-Cter in ubiquitin); alternate"
FT                   /evidence="ECO:0000250|UniProtKB:Q9Y6K9"
FT   CROSSLNK        314
FT                   /note="Glycyl lysine isopeptide (Lys-Gly) (interchain with
FT                   G-Cter in ubiquitin)"
FT                   /evidence="ECO:0000269|PubMed:17728323"
FT   CROSSLNK        318
FT                   /note="Glycyl lysine isopeptide (Lys-Gly) (interchain with
FT                   G-Cter in ubiquitin)"
FT                   /evidence="ECO:0000269|PubMed:17728323"
FT   CROSSLNK        319
FT                   /note="Glycyl lysine isopeptide (Lys-Gly) (interchain with
FT                   G-Cter in ubiquitin)"
FT                   /evidence="ECO:0000269|PubMed:17728323"
FT   CROSSLNK        392
FT                   /note="Glycyl lysine isopeptide (Lys-Gly) (interchain with
FT                   G-Cter in ubiquitin)"
FT                   /evidence="ECO:0000269|PubMed:17728323"
FT   MUTAGEN         278
FT                   /note="K->R: Slight decrease in TRAF6-induced
FT                   polyubiquitination."
FT                   /evidence="ECO:0000269|PubMed:17728323"
FT   MUTAGEN         293
FT                   /note="V->A: Abolishes linear polyubiquitin-binding,
FT                   impairs 'Lys-63'-linked polyubiquitin-binding and impairs
FT                   NF-kappa-B activation; when associated with A-301 and A-
FT                   302."
FT                   /evidence="ECO:0000269|PubMed:19303852"
FT   MUTAGEN         301
FT                   /note="Y->A: Abolishes linear polyubiquitin-binding,
FT                   impairs 'Lys-63'-linked polyubiquitin-binding and impairs
FT                   NF-kappa-B activation; when associated with A-293 and A-
FT                   302."
FT                   /evidence="ECO:0000269|PubMed:19303852"
FT   MUTAGEN         302
FT                   /note="K->A: Abolishes linear polyubiquitin-binding,
FT                   impairs 'Lys-63'-linked polyubiquitin-binding and impairs
FT                   NF-kappa-B activation; when associated with A-293 and A-
FT                   301."
FT                   /evidence="ECO:0000269|PubMed:19303852"
FT   MUTAGEN         305
FT                   /note="F->A: Abolishes linear polyubiquitin-binding,
FT                   impairs 'Lys-63'-linked polyubiquitin-binding and impairs
FT                   of NF-kappa-B activation."
FT                   /evidence="ECO:0000269|PubMed:19303852"
FT   MUTAGEN         309
FT                   /note="R->A: Abolishes linear polyubiquitin-binding, no
FT                   effect on 'Lys-63'-linked polyubiquitin-binding and impairs
FT                   NF-kappa-B activation; when associated with A-312 and A-
FT                   313."
FT                   /evidence="ECO:0000269|PubMed:19303852"
FT   MUTAGEN         312
FT                   /note="R->A: Abolishes linear polyubiquitin-binding, no
FT                   effect on 'Lys-63'-linked polyubiquitin-binding and impairs
FT                   NF-kappa-B activation; when associated with A-309 and A-
FT                   313."
FT                   /evidence="ECO:0000269|PubMed:19303852"
FT   MUTAGEN         313
FT                   /note="E->A: Impairs linear polyubiquitin-binding.
FT                   Abolishes linear polyubiquitin-binding, no effect on 'Lys-
FT                   63'-linked polyubiquitin-binding and impairs NF-kappa-B
FT                   activation; when associated with A-309 and A-312. Abolishes
FT                   linear polyubiquitin-binding; when associated with A-317
FT                   and A-320."
FT                   /evidence="ECO:0000269|PubMed:19303852"
FT   MUTAGEN         314
FT                   /note="K->R: Slight decrease in TRAF6-induced
FT                   polyubiquitination. Important decrease in TRAF6-induced
FT                   polyubiquitination; when associated with R-318 and R-319."
FT                   /evidence="ECO:0000269|PubMed:17728323"
FT   MUTAGEN         316
FT                   /note="V->P: Loss of interaction with TRAF6 and TRAF6-
FT                   induced polyubiquitination."
FT                   /evidence="ECO:0000269|PubMed:17728323"
FT   MUTAGEN         317
FT                   /note="E->A: Abolishes linear polyubiquitin-binding; when
FT                   associated with A-313 and A-320."
FT                   /evidence="ECO:0000269|PubMed:19303852"
FT   MUTAGEN         318
FT                   /note="K->R: Slight decrease in TRAF6-induced
FT                   polyubiquitination. Decrease in TRAF6-induced
FT                   polyubiquitination; when associated with R-319. Important
FT                   decrease in TRAF6-induced polyubiquitination; when
FT                   associated with R-314 and R-319."
FT                   /evidence="ECO:0000269|PubMed:17728323"
FT   MUTAGEN         319
FT                   /note="K->R: Slight decrease in TRAF6-induced
FT                   polyubiquitination. Decrease in TRAF6-induced
FT                   polyubiquitination; when associated with R-318. Important
FT                   decrease in TRAF6-induced polyubiquitination; when
FT                   associated with R-314 and R-318."
FT                   /evidence="ECO:0000269|PubMed:17728323"
FT   MUTAGEN         320
FT                   /note="E->A: Abolishes linear polyubiquitin-binding; when
FT                   associated with A-313 and A-317."
FT                   /evidence="ECO:0000269|PubMed:19303852"
FT   MUTAGEN         369
FT                   /note="S->A: Decreases phosphorylation and increases NF-
FT                   kappa-B activity."
FT                   /evidence="ECO:0000269|PubMed:11971901"
FT   MUTAGEN         375
FT                   /note="S->A: Decreases phosphorylation and increases NF-
FT                   kappa-B activity."
FT                   /evidence="ECO:0000269|PubMed:11971901"
FT   MUTAGEN         392
FT                   /note="K->R: 40% decrease in IL1-induced NF-kappa-B
FT                   activation."
FT                   /evidence="ECO:0000269|PubMed:17728323"
FT   CONFLICT        13
FT                   /note="M -> T (in Ref. 1; AAC40153)"
FT                   /evidence="ECO:0000305"
FT   HELIX           253..289
FT                   /evidence="ECO:0007744|PDB:4OWF"
FT   HELIX           291..333
FT                   /evidence="ECO:0007744|PDB:4OWF"
FT   HELIX           337..340
FT                   /evidence="ECO:0007744|PDB:3JSV"
SQ   SEQUENCE   412 AA;  47972 MW;  66C693C857A2D5E6 CRC64;
     MNKHPWKNQL SEMVQPSGGP AEDQDMLGEE SSLGKPAMLH LPSEQGTPET LQRCLEENQE
     LRDAIRQSNQ MLRERCEELL HFQVSQREEK EFLMCKFQEA RKLVERLSLE KLDLRSQREQ
     ALKELEQLKK CQQQMAEDKA SVKAQVTSLL GELQESQSRL EAATKDRQAL EGRIRAVSEQ
     VRQLESEREV LQQQHSVQVD QLRMQNQSVE AALRMERQAA SEEKRKLAQL QAAYHQLFQD
     YDSHIKSSKG MQLEDLRQQL QQAEEALVAK QELIDKLKEE AEQHKIVMET VPVLKAQADI
     YKADFQAERH AREKLVEKKE YLQEQLEQLQ REFNKLKVGC HESARIEDMR KRHVETPQPP
     LLPAPAHHSF HLALSNQRRS PPEEPPDFCC PKCQYQAPDM DTLQIHVMEC IE
//
